Investors reassess GLP-1 pill market amid Novo Nordisk's Wegovy launch

Early performance of Novo Nordisk's Wegovy pill is prompting investors to reconsider Eli Lilly & Co.'s previously assumed dominance in the GLP-1 pill market.

4 May, 18:04 — 4 May, 18:04

Post Share

Sources

Showing 1 of 1 sources

cnbcMostly Factual24d ago

Novo Nordisk’s Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

Read full article →

PERSPECTA

PERSPECTA

Investors reassess GLP-1 pill market amid Novo Nordisk's Wegovy launch

Sources

Novo Nordisk’s Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance

Related Stories

Extreme Training: What Heat Training Does to the Body

Red Tide Warning Issued in Pangasinan, Philippines

Kimchi Study Explores Role in Microplastic Removal

AstraZeneca's Imfinzi Approved for Additional Bladder Cancer Type

PERSPECTA